Cairn Therapeutics, Inc.
Cairn Therapeutics is dedicated to making cancer treatment simpler and safer, with a focus on developing potent, broadly applicable, and well-tolerated cancer therapies. Their lead candidate, CT-262, demonstrates exceptional efficacy and potential to overcome resistance mechanisms, aiming to improve outcomes for patients with various solid and hematological tumors.
Industries
Nr. of Employees
small (1-50)
Products
Lead duocarmycin-derived small-molecule cytotoxic candidate
A small-molecule DNA-alkylating cytotoxic development candidate designed for high potency across solid and hematologic tumors, with claimed reduced myelosuppression and resistance evasion relative to standard chemotherapies.
Lead duocarmycin-derived small-molecule cytotoxic candidate
A small-molecule DNA-alkylating cytotoxic development candidate designed for high potency across solid and hematologic tumors, with claimed reduced myelosuppression and resistance evasion relative to standard chemotherapies.
Services
Preclinical efficacy and safety studies
Design and execution of preclinical programs including 2D cell assays, human tumor organoid testing, in vivo mouse efficacy and survival studies, and hematological toxicity assessments.
Preclinical efficacy and safety studies
Design and execution of preclinical programs including 2D cell assays, human tumor organoid testing, in vivo mouse efficacy and survival studies, and hematological toxicity assessments.
Expertise Areas
- Oncology drug discovery
- Preclinical efficacy testing
- Translational medicine and biomarker development
- Clinical development and first‑in‑human trials
Key Technologies
- Human tumor organoid models
- In vivo mouse tumor models (leukemia, breast cancer, metastasis models)
- 2D cancer cell line cytotoxicity panels
- Survival analysis in animal studies